Newsroom

Discover our latest news

February 13, 2017:
Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference

December 28, 2016:
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV

December 05, 2016:
Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases

COMPLEMENT SYMPOSIUM HOSTED BY ACHILLION

Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, provided the opening remarks at the first Complement Symposium, hosted by Achillion, which was held in Orlando, Florida during the American Society of Hematology 2015 Annual Meeting, December 6, 2015.

Dr. Peter Densen, M.D., Professor of Internal Medicine – Infectious Disease, University of Iowa, provided a detailed look at the role of thecomplement system and the relative risks of infection associated with immune modulation.


Dr. Scott Barnum, Ph.D., Department of Microbiology at the University of Alabama at Birmingham, presented a review of complement immune-biology and the roles of the classical, lectin, and alternative pathways.


Dr. David Apelian, M.D., Ph.D., Chief Medical Officer of Achillion Pharmaceuticals, discussing the nomination of ACH-4471, small-molecule complement factor D inhibitor, being developed for the treatment of ultra-rare diseases, including PNH.